Letters
29 December 2022
Vol. 15 No. 2 (2023)
Lenvatinib-induced severe generalized erythematous rash in a patient with hepatocellular carcinoma
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
725
Views
368
Downloads
30
HTML
Authors
Not available
Altmetrics
Downloads
Download data is not yet available.
Citations
Hao Z, Wang P. Lenvatinib in Management of Solid Tumors. Oncologist 2020; 25(2): e302-e310. DOI: 10.1634/theoncologist.2019-0407. DOI: https://doi.org/10.1634/theoncologist.2019-0407
Haddad RI, Schlumberger M, Wirth LJ et al. Incidence and timing of common adverse events in Lenvatinib treated patients from the SELECT trial and their association with survival outcomes. Endocrine 2017; 56(1): 121-128. DOI: 10.1007/s12020-017-1233-5. DOI: https://doi.org/10.1007/s12020-017-1233-5
Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. DOI: https://doi.org/10.1016/S0140-6736(18)30207-1
Iwamoto H, Suzuki H, Shimose S et al. Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability toward Adverse Events. Cancers (Basel) 2020; 12(4). DOI: 10.3390/cancers12041010. DOI: https://doi.org/10.3390/cancers12041010
Ikeda M, Fujita T, Mii S et al. Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma. Jpn J Clin Oncol 2012; 42(9): 820-824. DOI: 10.1093/jjco/hys103. DOI: https://doi.org/10.1093/jjco/hys103
How to Cite
Lenvatinib-induced severe generalized erythematous rash in a patient with hepatocellular carcinoma. (2022). Dermatology Reports, 15(2). https://doi.org/10.4081/dr.2023.9617
Copyright (c) 2022 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
